Aetna modified CPB 0353 covering transcranial Doppler ultrasonography, effective September 26, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated its transcranial Doppler ultrasonography (TDU) coverage policy under CPB 0353 in Aetna's clinical policy system. The revision affects CPT codes 93886, 93888, 93890, 93892, 93893, 93896, 93897, and 93898 — the full set of TDU study codes. If your practice bills these codes to Aetna for neurology, vascular surgery, or pediatric patients, audit your indications now against the updated criteria before September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna (Aetna, a CVS Health company) |
| Policy | Transcranial Doppler Ultrasonography |
| Policy Code | CPB 0353 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Neurology, Vascular Surgery, Pediatric Hematology, Neonatology, Cardiovascular Medicine |
| Key Action | Verify that all active TDU orders map to one of the 15 covered indications and update ICD-10 coding accordingly before September 26, 2025. |
Aetna Transcranial Doppler Ultrasonography Coverage Criteria and Medical Necessity Requirements 2025
Aetna's coverage policy for TDU is driven entirely by clinical indication. There is no blanket approval for the procedure. Aetna covers CPT codes 93886 through 93898 only when the claim documents one of 15 specific medical necessity criteria.
This is a relatively broad coverage policy as payer TDU policies go. Fifteen covered indications is more than most commercial payers publish. The real risk isn't the list being too narrow — it's that your ICD-10 coding doesn't match the documented clinical reason for the study.
Here are all 15 covered indications under CPB 0353:
| # | Covered Indication |
|---|---|
| 1 | Assessing collateral blood flow and embolization during carotid endarterectomy |
| 2 | Assessing patterns and extent of collateral circulation in persons with known severe stenosis or occlusion, including Moyamoya syndrome |
| 3 | Assessing persons suspected of patent foramen ovale or paradoxical embolism (presenting with visual disturbance, weakness, hemiplegia, or slurred speech) |
| 4 | Assessing persons with suspected brain death |
| 5 | Assessing stroke risk in children ages 2–16 with sickle cell anemia (re-screening recommended approximately every six months per accepted guidelines) |
| 6 | Detecting arterio-venous malformations (AVMs) and studying their supply arteries and flow patterns |
| 7 | Detecting noncardiac right-to-left shunts |
| 8 | Detecting microemboli in cerebral artery embolism following stroke or transient ischemic attack (TIA) |
| 9 | Detecting severe stenosis in major basal intracranial arteries in members with neurological signs, symptoms, or carotid bruits |
| 10 | Diagnosing and monitoring reversible cerebral vasoconstriction syndromes |
| 11 | Diagnosing vertebral artery dissection |
| 12 | Evaluating and following vasoconstriction of any cause, especially after subarachnoid hemorrhage |
| 13 | Evaluating giant cell arteritis (temporal arteritis) |
| 14 | Evaluating intracranial occlusive disease in individuals with documented stroke or TIA |
| 15 | Evaluating very low birth weight preterm infants with gestational age under 30 weeks |
The policy says "any" of the above — meaning one qualifying indication is enough. Prior authorization requirements vary by plan, so check the specific Aetna product before scheduling. For high-volume TDU programs, especially pediatric sickle cell screening, confirm whether your plan tier requires prior auth for the 93886 complete study versus the 93888 limited study.
Reimbursement for these codes ties directly to medical necessity documentation. If the clinical note doesn't support one of these 15 indications, Aetna's claim review process will flag it. Your documentation needs to name the indication explicitly — not just list the diagnosis codes.
Aetna Transcranial Doppler Ultrasonography Exclusions and Non-Covered Indications
CPB 0353 doesn't publish a lengthy "not covered" list, but the structure of the policy creates implicit exclusions. Coverage requires meeting one of the 15 indications above. Any TDU study ordered outside those parameters is not covered under this coverage policy.
The practical exclusions your team should flag:
| # | Excluded Procedure |
|---|---|
| 1 | Routine cerebrovascular surveillance without documented stenosis, occlusion, neurological symptoms, or carotid bruits doesn't meet indication #9. |
| 2 | Screening in adult sickle cell patients isn't listed. The policy specifically covers children ages 2–16. Adults with sickle cell disease fall outside this indication as written. |
| 3 | TDU in preterm infants 30 weeks gestational age or older doesn't meet indication #15. The cutoff is gestational age under 30 weeks. |
| 4 | General dementia or cognitive screening without a qualifying neurological finding is not listed among the 15 indications. |
If your clinical team is ordering TDU for indications outside these 15, that's a claim denial waiting to happen. Talk to your compliance officer before continuing to bill those cases to Aetna.
Coverage Indications at a Glance
| Indication | Status | Primary CPT Codes | Notes |
|---|---|---|---|
| Carotid endarterectomy — collateral flow and embolization | Covered | 93886, 93892, 93893 | Intraoperative use |
| Collateral circulation assessment — severe stenosis or occlusion, incl. Moyamoya | Covered | 93886, 93888 | Must document known stenosis/occlusion |
| Suspected patent foramen ovale / paradoxical embolism | Covered | 93893, 93897, 93898 | Symptoms must be documented (visual disturbance, weakness, hemiplegia, slurred speech) |
| Suspected brain death | Covered | 93886 | |
| Sickle cell anemia — stroke risk in children ages 2–16 | Covered | 93886, 93888 | Re-screen ~every 6 months; adults not covered under this indication |
| AVM detection and supply artery flow patterns | Covered | 93886, 93888 | |
| Noncardiac right-to-left shunt detection | Covered | 93893, 93898 | |
| Microemboli detection post-stroke or TIA | Covered | 93892, 93893, 93897, 93898 | |
| Severe intracranial stenosis — neurological signs/symptoms or carotid bruits | Covered | 93886, 93888 | Neurological indication required |
| Reversible cerebral vasoconstriction syndrome — diagnosis and monitoring | Covered | 93886, 93890, 93896 | |
| Vertebral artery dissection diagnosis | Covered | 93886, 93888 | |
| Vasoconstriction evaluation — post-subarachnoid hemorrhage or other cause | Covered | 93890, 93896 | |
| Giant cell arteritis (temporal arteritis) | Covered | 93886, 93888 | |
| Intracranial occlusive disease — documented stroke or TIA | Covered | 93886, 93888 | Documented stroke or TIA required |
| Very low birth weight preterm infants — gestational age under 30 weeks | Covered | 93886, 93888 | Gestational age cutoff is strict |
| TDU outside the 15 listed indications | Not Covered | All TDU CPT codes | No clinical indication match |
| Adult sickle cell stroke surveillance | Not Covered | 93886, 93888 | Only children ages 2–16 covered |
| Preterm infants ≥ 30 weeks gestational age | Not Covered | 93886, 93888 | Strict gestational age cutoff |
Aetna Transcranial Doppler Ultrasonography Billing Guidelines and Action Items 2025
The updated CPB 0353 is active September 26, 2025. These are the steps your billing team should take now.
| # | Action Item |
|---|---|
| 1 | Audit your active TDU orders before September 26, 2025. Pull all pending and recurring TDU orders. Match each one to one of the 15 covered indications. Flag any that don't clearly fit. Don't wait until you get a denial. |
| 2 | Update charge capture to require indication documentation. Your charge capture workflow for CPT 93886, 93888, 93890, 93892, 93893, 93896, 93897, and 93898 should require the ordering provider to document the specific clinical indication from the CPB 0353 list — not just a diagnosis code. |
| 3 | Tighten ICD-10 pairing for sickle cell pediatric TDU. For children with sickle cell anemia (ICD-10 D57.00–D57.819), confirm the patient age is documented as 2–16. Bill 93886 or 93888 depending on whether you're running a complete or limited study. Set a re-screening schedule at approximately every six months and document it in the clinical record. |
| 4 | Separate complete from limited study billing correctly. CPT 93886 is the complete TDU study. CPT 93888 is the limited study. These aren't interchangeable. Bill based on what was actually performed and documented. Upcoding from 93888 to 93886 without documentation of a complete study is a fast path to claim denial. |
| 5 | Flag the emboli detection code pair. CPT 93892 covers emboli detection without intravenous microbubble injection. CPT 93893 covers emboli detection with injection. The distinction matters — document whether microbubble contrast was used. The newer add-on codes 93897 and 93898 reflect the same split for studies performed alongside a complete TDU (93886 or 93896). Bill the right code for what you did. |
| 6 | Verify prior authorization requirements by Aetna plan tier. CPB 0353 establishes the medical necessity criteria, but prior authorization requirements vary by product. Commercial HMO products often require prior auth where PPO products don't. Check each patient's specific Aetna plan before scheduling high-cost complete studies. |
| 7 | Check preterm neonatal protocols. If your NICU or neonatology practice bills TDU for preterm infants, confirm every case documents gestational age under 30 weeks. This is a hard cutoff in the policy. Missing or vague gestational age documentation is a denial risk. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Transcranial Doppler Ultrasonography Under CPB 0353
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 93886 | CPT | Transcranial Doppler study of the intracranial arteries; complete study |
| 93888 | CPT | Transcranial Doppler study of the intracranial arteries; limited study |
| 93890 | CPT | Transcranial Doppler study of the intracranial arteries; vasoreactivity study |
| 93892 | CPT | Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection |
| 93893 | CPT | Transcranial Doppler study of the intracranial arteries; emboli detection with intravenous microbubble injection |
| 93896 | CPT | Vasoreactivity study performed with transcranial Doppler study of intracranial arteries, complete |
| 93897 | CPT | Emboli detection without intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete |
| 93898 | CPT | Venous-arterial shunt detection with intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete |
Related CPT Code
| Code | Type | Description |
|---|---|---|
| 61635 | CPT | Transcatheter placement of intravascular stent(s), intracranial (e.g., atherosclerotic stenosis), including balloon angioplasty |
Key ICD-10-CM Diagnosis Codes
This is a partial list of the 250 ICD-10-CM codes covered under CPB 0353. Confirm the full list at the Aetna CPB 0353 policy page.
| Code / Range | Description |
|---|---|
| D57.00–D57.819 | Sickle-cell disorders (for evaluating children ages 2–16) |
| G45.0 | Vertebro-basilar artery syndrome |
| G45.8 | Other transient cerebral ischemic attacks and related syndromes |
| G45.9 | Transient cerebral ischemic attack, unspecified |
| G93.1 | Anoxic brain damage, not elsewhere classified |
| G93.5 | Compression of brain |
| G93.7 | Reye's syndrome |
| G93.89–G93.9 | Other and unspecified disorders of the brain |
| G90.01–G91.9 | Other disorders of the autonomic nervous system and hydrocephalus |
| G43.001–G43.919 | Migraine |
| G40.001–G40.919 | Epilepsy and recurrent seizures |
| G00.0–G09 | Inflammatory diseases of the central nervous system |
| G10–G12.9 | Systemic atrophies primarily affecting the central nervous system |
| G20.A1–G26 | Extrapyramidal and movement disorders |
| G30.0–G32.89 | Other degenerative diseases of the nervous system |
| G80.3 | Athetoid cerebral palsy |
| C71.0–C71.9 | Malignant neoplasm of brain |
| C79.31–C79.49 | Secondary malignant neoplasm of brain and nervous system |
| D33.0–D33.2 | Benign neoplasm of brain |
| D43.0–D43.4 | Neoplasm of uncertain behavior of brain and spinal cord |
| D49.6 | Neoplasm of unspecified behavior of brain |
| A17.0–A17.9 | Tuberculosis of meninges and central nervous system |
| B50.0 | Plasmodium falciparum malaria with cerebral complications |
| E75.00–E75.19, E75.23, E75.25, E75.29, E75.4 | Disorders of sphingolipid metabolism and other lipid storage disorders |
| F01.50–F99 | Mental and behavioral disorders (select codes where neurological workup applies) |
| F84.2 | Rett's syndrome |
The full ICD-10-CM list for CPB 0353 contains 250 codes. If your ICD-10 doesn't appear in the covered list and you're unsure whether it supports one of the 15 indications, talk to your compliance officer before billing.
Get the Full Picture for CPT 93886
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.